#348 How to Slow the Flow III: Tranexamic acid for heavy menstrual bleeding
CLINICAL QUESTION
In premenopausal heavy menstrual bleeding due to benign etiology, does tranexamic acid (TXA) improve patient outcomes?
BOTTOM LINE
TXA is more effective than placebo, progestins, or NSAIDs. Menstrual blood loss is reduced in ~40% of women with TXA compared to ~10% with placebo, with 5-10 fewer sanitary items used/cycle. Adverse events are similar to placebo. However, more women benefit from a levonorgestrel intrauterine device (IUD) than TXA (~60% versus 30%). Effects on bleeding duration and flooding are inconsistent.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Statistically significant unless noted.
- One systematic review,1 13 randomized controlled trials (RCTs). After 2-6 cycles:
- Versus placebo (4 RCTs, 16-304 patients):1-5
- Proportion with clinically detectable blood loss improvement: 39% versus 11% placebo.1
- Mean blood loss 53mL/cycle lower with TXA (baseline 153-268mL).1
- Example: Mean blood loss reduced 40% (70ml) versus 8% (13ml) (placebo).5
- Sanitary items used per cycle: 20-27 versus 25-36 placebo.2,3
- Bleeding duration,2,3 “large stains”4,5 (not defined): No difference.
- Quality of life: Not clinically different.4,5
- Adverse effects: No difference.1-5
- Versus progestins (6 RCTs, 46-128 patients):1,6-9
- Proportion with clinically detectable blood loss improvement: 71% versus 46% progestins.1
- Mean blood loss: Inconsistent; largest RCTs6,7 show no difference.
- Sanitary items: No difference.8
- Bleeding duration: Reduced 1-2 days versus 0.3-2 days progestin.6,7
- Flooding/leakage reported “better”: 83% versus 45% progestin.8
- Adverse effects (examples headaches, spotting): 21% versus 32% progestin.1
- Versus levonorgestrel intrauterine device (IUD) (1 RCT, 42 patients):1,9
- Proportion with clinically detectable blood loss improvement: 29% versus 61% IUD.
- Quality of life, adverse effects: No difference.
- Versus mefenamic acid (1 RCT, 49 patients):1,10
- Proportion with clinically detectable blood loss improvement: 87% versus 61% mefenamic acid.1
- Mean blood loss reduced from 164 to 75ml versus 186 to 148ml mefenamic acid.10
- Sanitary items, bleeding duration, adverse events: No difference.10
- Versus placebo (4 RCTs, 16-304 patients):1-5
- Other meta-analysis11 found similar.
- Limitations: Many trials small and short, variable blood loss measurement methods, inconsistent fibroid inclusion, outcomes inconsistent, not all randomized patients included in analysis.
CONTEXT
- Although no increase in thromboembolic events in large bleeding/trauma studies, TXA should be avoided with thromboembolic history.12-15
- TXA costs ~$14/cycle.16
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
Nice to see the breakdown of number who can benefit
Great timely information
a non hormonal treatment for menorrhagia is always helpful
Reassuring to hear that this non-hormonal treatment has proven efficacy
This information was useful
Confirmed present practice
beneficial article
I have used TXA in the past for menorrhagia/dysfunctional uterine bleeding and I will resume this practice.
Very helpful. Have been overly concerned about se with TxA in the past